<DOC>
	<DOCNO>NCT02686424</DOCNO>
	<brief_summary>Gastric cancer one leading cause cancer-related death worldwide . Despite advance therapeutic intervention , mortality disease remain high . As result , patient offer vary combination surgery , chemotherapy , radiation therapy order derive benefit multidisciplinary approach . Unfortunately , therapy often toxic debilitate therapeutic response vary . Thus new therapeutic strategy require treatment gastric cancer . In early 1980s , discovery cytolytic T cell ( cytolytic T lymphocyte , CTLs ) direct antigen present tumor cell publish . They kill many invasive cell recognize tumor specific antigens major histocompatibility complex ( MHC ) molecules . It generally agree although tumor express tumor antigen , usually lack immunogenicity inability activate immune response . The current view tumor cell antigenic , immunogenic . If artificially activate immune system tumor , may possible eradicate tumor . This approach basis cancer immunotherapy . Many tumor antigen define term multiple solid tumor : MART-1/Melan-A , gp100 , carcinoembryonic antigen ( CEA ) , HER-2 , mucin ( i.e. , MUC-1 ) , prostate-specific antigen ( PSA ) , prostatic acid phosphatase ( PAP ) short list . Some immune-based therapy target tumor antigen phase III trial assess whether immunize antigen affect overall survival . In gastric cancer , tumor antigen MAGE-A3 , NY-ESO-1 , WT-1 report express substantial proportion case . They potential target molecule immunotherapy future . In study , aim explore expression level four tumor marker ( MAGE-A3 , NY-ESO-1 , WT-1 PRAME ) gastric cancer Korean patient examine correlation expression level four marker clinic-patholoical factor .</brief_summary>
	<brief_title>Tumor Markers Study Gastric Cancer Cancer Immunotherapy ( ONCO-RD 010 CRT )</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<criteria>gastric carcinoma receive gastrectomy neoadjuvant therapy</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>MAGE-A3 protein</keyword>
	<keyword>NY-ESO-1 protein</keyword>
	<keyword>WT1 Proteins</keyword>
	<keyword>PRAME protein</keyword>
</DOC>